Business Context and Reporting Period
Company: Greenwich LifeSciences, Inc. (GLSI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 12, 2022
Reporting Period: Event date of July 12, 2022
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing reports the entry into a material definitive agreement to raise capital.
Key Financial Metrics and Transaction Details
This filing does not report periodic financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a new financing arrangement:
- Agreement Type: Open Market Sale Agreement ("At-the-Market" offering).
- Counterparty: Jefferies LLC (acting as sales agent).
- Maximum Offering Size: Up to $100.0 million in aggregate offering price.
- Commission Rate: Up to 3.0% of gross proceeds.
- Registration Basis: Shelf registration statement on Form S-3 (File No. 333-263855).
Material Changes
The material change reported is the execution of the Sale Agreement on July 12, 2022. This agreement grants the Company the option, but not the obligation, to sell shares of its common stock through Jefferies. The Company may suspend the offering at any time upon notice. No sales of shares are guaranteed under this agreement.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use net proceeds for general corporate purposes, specifically including:
- Funding clinical development and manufacturing expenses for GP2.
- Research and development (R&D).
- General and administrative expenses.
- License or technology acquisitions.
- Working capital and capital expenditures.
Risks and Contingencies: The filing notes that the Company has no obligation to sell any shares and may suspend the offering. The report explicitly states it does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of GLSI common stock to assess potential dilution from future sales under the $100 million cap.
- Review the attached Exhibit 1.1 (Open Market Sale Agreement) for specific termination provisions and conditions.
- Monitor subsequent filings (e.g., Form 4 or 8-K) to track actual share sales and proceeds generated under this agreement.
- Confirm the status of the GP2 clinical development program, as it is a primary stated use of proceeds.